Breaking News

AGC Biologics to Manufacture Peanut Allergy Vax Candidate

To produce vaccine materials at its Heidelberg facilities for Allergy Therapeutics' early-stage trials.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AGC Biologics, a biopharmaceutical CDMO, entered a partnership with Allergy Therapeutics, to manufacture clinical trial materials for Allergy Therapeutics’ virus-like particle (VLP)-based peanut allergy vaccine candidate.   AGC Biologics is supporting the manufacturing and testing of the VLP Peanut vaccine candidate, providing VLP material for Phase I supply. The FDA recently cleared Allergy Therapeutics Investigational New Drug application (IND), which included data generated in this collabor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters